Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | UNG | P13051 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | NAT1 | P18440 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3645563 | 0.87 | MAOA (0.46) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL30954279 | 0.86 | MAOA (0.41) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL6841543 | 0.83 | ALDH1A1 (0.41) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL16334979 | 0.83 | HMGCR (0.43) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL18714200 | 0.82 | TP53 (0.46) | MAOBALDH1A1TDP1HMGCRPTGS2 | |
| SCHEMBL25949907 | 0.82 | SLC6A2 (0.52) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL13509648 | 0.81 | MAOA (0.41) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL3693386 | 0.80 | ATM (0.39) | MAOBGGPS1 | |
| SCHEMBL7141602 | 0.78 | MAOA (0.45) | MAOAMAOBUNGALDH1A1RAB9A | |
| SCHEMBL3428859 | 0.78 | MAOA (0.38) | MAOAMAOBUNGALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20140329797-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-20140329797-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| US-20140329797-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-06 | — | — | US | disclosed |
| EP-2768826-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | Bayer Intellectual Property GmbH (DE) | 2014-08-27 | — | — | EP | disclosed |
| EP-2734505-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-05-28 | — | — | EP | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| WO-2013057101-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057101-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-25 | — | — | WO | disclosed |
| EP-2569309-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013011033-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013011033-A1 | 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-24 | — | — | WO | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329797-A1 | SUBSTITUTED OXADIAZOLYL PYRIDINONES AND OXADIAZOLYL PYRIDAZINONES AS HIF INHIBITORS | HIF1AN, HIF1A, EGLN3 | MAOA 1910/4885MAOB 1502/4885UNG 1519/4885 |
| US-20130150325-A1 | 3-(Fluorovinyl)pyrazoles and their use | VHL, HIF1AN, HIF1A | MAOA 2120/4885MAOB 1537/4885UNG 1600/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MAOA 2176/4885MAOB 1738/4885UNG 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.